Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CEL | P19835 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346579 | 0.95 | JAK2 (0.35) | DAOJAK2JAK1BRD4ROCK2 | |
| SCHEMBL8126131 | 0.82 | DAO (0.40) | DAOBRD4 | |
| SCHEMBL2172919 | 0.71 | DAO (0.38) | DAOJAK2JAK1BRD4ROCK2 | |
| SCHEMBL10110509 | 0.71 | NOS3 (0.35) | DAOBRD4 | |
| SCHEMBL9284095 | 0.70 | AURKA (0.34) | DAOJAK2BRD4 | |
| SCHEMBL17060505 | 0.70 | DAO (0.34) | DAOBRD4 | |
| SCHEMBL17536383 | 0.68 | CEL (0.38) | CELPDE9A | |
| SCHEMBL27157561 | 0.68 | DAO (0.36) | DAOJAK2JAK1BRD4CEL | |
| SCHEMBL1346010 | 0.67 | GPR84 (0.43) | DAO | |
| SCHEMBL14883963 | 0.66 | PSMB5 (0.39) | DAOBRD4CELCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063055-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | KIT, CMA1, C3AR1 | DAO 1887/4885JAK2 174/4885JAK1 158/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | DAO 1887/4885JAK2 174/4885JAK1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.